If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Baricitinib
Olumiant® (baricitinib) tablets
1mg, 2mg, 4mgbaricitinib
1mg, 2mg, 4mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the mechanism of action of OLUMIANT® (baricitinib) in rheumatoid arthritis?
Olumiant (baricitinib) is a selective and reversible inhibitor of the JAK family of protein tyrosine kinases, specifically JAK1 and JAK2.
See important safety information, including boxed warning, in the attached prescribing information.
The Role of Cytokines and JAKs in Rheumatoid Arthritis
Rheumatoid arthritis is associated with an abnormal production of pro-inflammatory cytokines and growth factors.1-3 Many pro-inflammatory cytokines, including interleukin (IL)-2, IL-6, IL-12, interferon (IFN)-alpha, IFN-beta, and IFN-gamma, and granulocyte/macrophage colony-stimulating factor (GM-CSF), require members of the Janus kinase (JAK) family of protein tyrosine kinases (JAK1, JAK2, JAK3, and tyrosine kinase [TYK] 2) to transduce signals across cell membranes.2,4-6
Inside the cell, JAKs facilitate the transfer of a phosphate group from adenosine triphosphate (ATP) to signal transducers and activators of transcription (STATs) via autophosphorylation and transphosphorylation.6 This reversible phosphorylation activates the STATs and allows them to
Mechanism of Action of Baricitinib
Baricitinib is a selective and reversible inhibitor of the JAK family of protein tyrosine kinases, specifically JAK1 and JAK2, with less selectivity for TYK2 and JAK3.2,5
Baricitinib modulates the JAK-STAT pathway, and, consequently, signaling by cytokines including IL-6, IFN, and GM-CSF, by transiently occupying the ATP binding pocket of the JAK. This prevents the phosphorylation of JAKs and the subsequent phosphorylation and activation of STATs.6,9
Janus kinase enzymes transmit cytokine signaling through their pairing, such as JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2. In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies.9
Janus kinase inhibition by baricitinib is transient and reversible.5 Baricitinib inhibits signaling through the JAK-STAT pathway for a portion of the day. Maximal inhibition occurs at 1 to 2 hours postdose and returns to baseline by 16 to 24 hours.2
In isolated enzyme assays, baricitinib exhibited
- selectivity for JAK1 with an IC50 (half maximal inhibitory concentration) of 5.9 nM and JAK2 with an IC50=5.7 nM
- 100-fold less selectivity for JAK3 with an approximate IC50 of 560 nM, and
- 10-fold less selectivity for TYK2 with an IC50 of 53 nM.5
The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.9
Mechanism of Action Video
A detailed visual representation of the mechanism of action of baricitinib may be accessed via the video link in the figure below VIDEO: Mechanism of Action of Baricitinib in RA.
Abbreviations: GM-CSF = granulocyte-macrophage colony-stimulating factor; JAK = janus kinase; IL = interleukin; TYK = tyrosine kinase.
Structural Description of Baricitinib
Baricitinib has
- an empirical formula of C16H17N7O2S,
- a molecular weight of 371.42, and
- the structural formula as shown in Baricitinib Structural Formula.9
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Malemud CJ, Pearlman E. Targeting JAK/STAT signaling pathway in inflammatory diseases. Curr Signal Transduct Ther. 2009;4(3):201-221. http://dx.doi.org/10.2174/157436209789057467
2Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54(12):1354-1361. http://dx.doi.org/10.1002/jcph.354
3Mateen S, Zafar A, Moin S, et al. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chimica Acta. 2016;455:161-171. http://dx.doi.org/10.1016/j.cca.2016.02.010
4Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223(1):132-142. http://dx.doi.org/10.1111/j.1600-065X.2008.00644.x
5Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298-5307. http://dx.doi.org/10.4049/jimmunol.0902819
6Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25-36. http://dx.doi.org/10.1038/nrrheum.2015.167
7Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21-27. http://dx.doi.org/10.4049/jimmunol.1401867
8O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161-170. http://dx.doi.org/10.1056/NEJMra1202117
9Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: November 06, 2023